Exact Mass: 786.2473047999999
Exact Mass Matches: 786.2473047999999
Found 31 metabolites which its exact mass value is equals to given mass value 786.2473047999999,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Estradiol mustard
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
Hydroxypropionic porphyrin III
Hydroxypropionic porphyrin III is a porphyrin isolated only in patients with porphyria cutanea tarda. Porphyria cutanea tarda (PCT) is a metabolic disorder of haeme biosynthesis caused by decreased activity of uroporphyrinogen decarboxylase. Porphyria cutanea tarda is manifest by fragility, erosions, bullae, milia and scars on sun-exposed skin. Excess porphyrins in the skin interact with light of approximately 400 nm-wavelength radiant energy, forming reactive oxygen species. Porphyria cutanea tarda is categorized as familial, acquired or toxic. Factors that may induce clinical expression of PCT in susceptible individuals include alcohol, oestrogen, iron, polyhalogenated compounds and viral infections. Porphyria cutanea tarda is associated with an increased incidence of the haemochromatosis gene. Treatments for PCT include withdrawal of aggravating factors, phlebotomy and oral antimalarial medications. Porphyria cutanea tarda is associated with hepatic iron overload and responds to iron-reduction therapy. Porphyria cutanea tarda is the most common porphyria, followed by acute intermittent porphyria and erythropoietic protoporphyria. The molecular genetics of the porphyrias is very heterogenous. (PMID: 16315139, 7655298, 11105361) [HMDB] Hydroxypropionic porphyrin III is a porphyrin isolated only in patients with porphyria cutanea tarda. Porphyria cutanea tarda (PCT) is a metabolic disorder of haeme biosynthesis caused by decreased activity of uroporphyrinogen decarboxylase. Porphyria cutanea tarda is manifest by fragility, erosions, bullae, milia and scars on sun-exposed skin. Excess porphyrins in the skin interact with light of approximately 400 nm-wavelength radiant energy, forming reactive oxygen species. Porphyria cutanea tarda is categorized as familial, acquired or toxic. Factors that may induce clinical expression of PCT in susceptible individuals include alcohol, oestrogen, iron, polyhalogenated compounds and viral infections. Porphyria cutanea tarda is associated with an increased incidence of the haemochromatosis gene. Treatments for PCT include withdrawal of aggravating factors, phlebotomy and oral antimalarial medications. Porphyria cutanea tarda is associated with hepatic iron overload and responds to iron-reduction therapy. Porphyria cutanea tarda is the most common porphyria, followed by acute intermittent porphyria and erythropoietic protoporphyria. The molecular genetics of the porphyrias is very heterogenous. (PMID: 16315139, 7655298, 11105361).
Heptacarboxylporphyrin I
Heptacarboxylporphyrin I is a bile product that arises from the conversion of Heptacarboxylporphyrinogen I to Heptacarboxylporphyrin I by porphyrinogen carboxy-lyase (EC 4.1.1.37). [HMDB] Heptacarboxylporphyrin I is a bile product that arises from the conversion of Heptacarboxylporphyrinogen I to Heptacarboxylporphyrin I by porphyrinogen carboxy-lyase (EC 4.1.1.37).
Pseudouroporphyrin
Porphyrins excreted in various types of porphyria (PubMed ID 5917679 ). Intermediate of haem biosynthesis (PubMed ID 1216185). Porphyrins excreted in various types of porphyria (PubMed ID 5917679 ).
Heptacarboxylic porphyrin
5,10-Methenyltetrahydromethanopterin; 5,10-Methenyl-5,6,7,8-tetrahydromethanopterin; N5,N10-Methenyltetrahydromethanopterin
C31H43N6O16P (786.2473047999999)
5,10-Methenyltetrahydromethanopterin
C31H43N6O16P (786.2473047999999)
6,6-[(3,3-Di-t-butyl-5,5-dimethoxy-1,1-biphenyl-2,2-diyl)bis(oxy)]bis(dibenzo[d,f][1,3,2]dioxaphosphepin)hemiethylacetateadduct,min.95BIPHEPHOS
C46H44O8P2 (786.2511284000001)
Aldoxorubicin hydrochloride
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
5,10-Methylene-tetrahydromethanopterin (iminium form)
C31H43N6O16P-2 (786.2473047999999)